Latest Prostate Cancer News from ESMO23

[marnieg46]

For those interested in the outcomes of recent prostate cancer trials or those just curious about the current thinking on 'where to next' the latest GU Cast podcast from Declan Murphy is well worth watching.

The presentation is ‘peppered’ with conversation from the various speakers interviewed that contain gems and insights into, not just the outcomes of the trials, but, often their own opinions on what went well and what might be worth pursuing further.

In this episode the topic of PSMA theranostics with Louise Emmett (ENZA-P) and Oliver Sartor (PSMAfore) is explored. Also discussed is the androgen receptor pathway inhibitors (ARPIs) in biochemical recurrence with Steve Freedland (EMBARK), Morgan Roupret and Boris Hadaschik. Christian Gratze discusses the latest negative immunotherapy trials in prostate cancer.

youtu.be/iXE63tBsqjE(Not working as expected?)

[Jbooml]

13 month 43% benefit over Enza alone? I’d like to hear about a 10 X benefit of just one of these trials. I didn’t know that de novo Enza treatment

[Jbooml in reply to Jbooml]

Meant to write that I didn’t know that Enza was used on its own

[MateoBeach]

Very good news on the Radioligand front especially for Lu177. Also good news for ARSI alone or in combo with ADT from high-risk (rapid PSADT) BCR, and beyond. Time to retire the PD1/PDL1 (Pembrolizumab) for unselected patients (it does not work!) The SOC marches ever on.